CagriSema registration in chronic kidney disease with type 2 diabetes lists four blinded arms

The source is a ClinicalTrials.gov registration for a human study in people with chronic kidney disease, type 2 diabetes and overweight or obesity. The registration text provided does not state the number of participants enrolled, so no sample size is reported here. The registration states the study "will look if CagriSema can lower kidney damage" in that population and describes CagriSema as a new investigational medicine that cannot yet be prescribed by doctors.

Four groups are described: CagriSema, semaglutide alone, cagrilintide alone, and placebo. The registration states that treatment assignment is decided by chance and that the study doctor will not know which of the study medicines a participant receives. The stated duration is about 35 weeks per participant.

Each active arm is paired with a matched placebo so that all participants receive two subcutaneous injections. The semaglutide arm receives semaglutide plus placebo matched to cagrilintide; the cagrilintide arm receives cagrilintide plus placebo matched to semaglutide; the placebo arm receives both matched placebos. This design, as written in the registration, allows the combination to be compared with each single agent and with no active ingredient.

Because this is a registration record rather than a results publication, no outcome data, no effect sizes and no adverse-event counts appear in the provided text.

The registration describes schedules rather than milligram amounts. The three active arms receive study medicine subcutaneously once weekly after a dose escalation period of 16 weeks, followed by a maintenance period of 10 weeks. The placebo arm receives matched placebo subcutaneously once weekly for 26 weeks. No specific doses in milligrams are stated anywhere in the provided registration text.

This is a registration-only record: it describes what the study intends to do, not what it found. No results, no participant numbers and no safety data appear in the provided text, and the registration does not state the specific milligram doses used in any arm.

Kidney damage is named as the subject of the study, but the provided excerpt does not define the measurement used, the statistical plan, the number of sites, or any funding or sponsor detail. Readers cannot judge from this text whether the design was adequately powered for the stated question.

Cagrilintide, studied alone and coformulated with semaglutide as CagriSema, is not an FDA-approved drug for any use. Consistent with that, the registration itself states that CagriSema cannot yet be prescribed by doctors.